Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

Arndt Vogel(Princess Margaret Cancer Centre), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Josefine Römmler-Zehrer, D. McGovern, Alfredo Romano(Bristol-Myers Squibb (Switzerland)), Jack Shiansong Li

BMC Cancer

October 20, 2016

10.1186/s12885-016-2798-8

Cited by 36

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

|Annals of Oncology|2022|1.4k

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

|Nature|2021|1.3k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.1k